About US
Contact us
-
Bayer gains key FDA expansion for fast-rising prostate cancer drug NubeqaBayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitorNubeqa, scoring an FDAapprovalto expand its use to all patients with metastatic castrat2025/6/5
-
Novo Nordisk signs on to support ADA’s obesity advocacy divisionAlmost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo Nordisk for support. The ADA’s obesity division went live last June, with a m2025/6/5
-
CDC vaccine expert resigns amid shifting COVID guidance: ReutersWith U.S. recommendations for COVID-19 vaccines in flux, a leading member of the CDC's COVID vaccine advisory group is reportedly jumping ship. Lakshmi Panagiotakopoulos, M.D., a nearly 10-year CDC e2025/6/3
-
ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flopDespite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the needle in resected skin cancer. Afterrevealingin February that Opdualag fail2025/6/3
-
ASCO: J&J's Akeega gives PARP a novel prostate cancer win, but FDA path in patient subset unclearThe FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC). Now, Johnson & Johnson’s Akeega is giving the class a win in castrat2025/5/29
-
Swiss CDMO Carbogen bolsters ADC production capability with $31M investmentDrugmakers and contract manufacturers are responding to the booming demand for antibody-drug conjugates, with multiple expansion projects announced in recent years to support the targeted cancer trea2025/5/29
-
Newly proposed EU drug regulations a 'missed opportunity' to support innovation, industry saysThe Council of the European Union has delivered its newest set of proposals meant to shake up European pharma regulations and sharpen the region's competitive edge, but the plan isn't exactly what EU2025/5/27
-
Schott Pharma throws down €100M to build new sterile cartridge facility at Hungary manufacturing siteA little less than a year after cutting the ribbon at a new glass syringe factory in Hungary, Schott Pharma is making good on its pledge to swiftly expand the site. Schott—which produces glass vials,2025/5/27
-
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer populationIn a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to expand Talzenna into a broader prostate cancer population has failed to impres2025/5/22
-
AstraZeneca, Merck duke it out at the top of oncologists’ pharma perception rankingAstraZeneca and Merck are still leading the pack when it comes to how oncologists perceive makers of cancer drugs, according to a new report from ZoomRx. Though Merck edged out AstraZeneca by a singl2025/5/22